Showing results (191-200 of 447) with videos related to
Sort By:
Pageof 45
Nature Reviews. Clinical Oncology|February 13, 2021
PD-L1 as a biomarker of response to immune-checkpoint inhibitorsDeborah Blythe Doroshow, Sheena Bhalla, Mary Beth Beasley, et al.Plos Biology|September 14, 2018
Refined RIP-seq protocol for epitranscriptome analysis with low input materialsYong Zeng, Shiyan Wang, Shanshan Gao, et al.Small (Weinheim an Der Bergstrasse, Germany)|December 4, 2009
HDL-mimicking peptide-lipid nanoparticles with improved tumor targetingZhihong Zhang, Juan Chen, Lili Ding, et al.Lung Cancer (Amsterdam, Netherlands)|October 12, 2004
Validating the prognostic value of marker genes derived from a non-small cell lung cancer microarray studyFiona H Blackhall, Dennis A Wigle, Igor Jurisica, et al.The Lancet. Oncology|January 15, 2021
Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trialB C John Cho, Laura Donahoe, Penelope A Bradbury, et al.Oncogene|September 13, 2002
The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosisQiang G Dong, Guido M Sclabas, Shuichi Fujioka, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 29, 2011
A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancerPeter M Ellis, Normand Blais, Dennis Soulieres, et al.Cancer Cell|November 26, 2015
A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to ChemotherapyIan G Cannell, Karl A Merrick, Sandra Morandell, et al.Frontiers in Oncology|August 18, 2022
Digital quantitative tissue image analysis of hypoxia in resected pancreatic ductal adenocarcinomasIram Siddiqui, Jade Bilkey, Trevor D McKee, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2005
A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancerHelen Mackay, David Hedley, Pierre Major, et al.Pageof 45